Methyl-bis (beta-chloroethyl)amine in large doses in the treatment of neoplastic diseases.
Sixty-seven patients with neoplastic diseases were treated with 151 courses of methylbis (beta-chloroethyl)amine hydrochloride (HN(2)). Seventy-seven of the courses consisted of single injections of 0.2 to 0.4 mg. per kilogram of body weight, and 35 courses were given as single injections of 0.6 mg. per kilogram of body weight.Twenty-three patients with Hodgkin's disease were treated. Remissions averaged approximately three months in 13 patients who were in good or fair general physical condition, and 1.5 months in 11 patients who were in poor or moribund condition; one of the 11 did not respond to the therapy. Fifteen patients with lymphosarcoma were treated. Remissions averaged between one and two months in four patients who were in good or fair general physical condition. Of the remaining 11 patients, two showed no response, and the longest remission among the remaining nine was approximately 40 days. Satisfactory remissions of one to three months were obtained in four patients with mycosis fungoides treated with single courses of 0.3 mg. per kilogram of body weight. Serious toxic reactions were observed in six patients, four of whom died. In five of the six instances the reactions consisted of pancytopenia and hemorrhagic diathesis. All these patients were in poor general or hematologic status before therapy. In general, large single doses of HN(2) were neither more nor less effective than the four-to six-day course usually employed with this agent. Combination of the administration of HN(2) with artificial hyperpyrexia, or with concurrent courses of pteroylglutamic conjugates, did not enhance the therapeutic effects of the agent.
D000588:Amines; D005260:Female; D006689:Hodgkin Disease; D006801:Humans; D008297:Male; D008466:Mechlorethamine; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D009588:Nitrogen Mustard Compounds
D000588:Amines; D009588:Nitrogen Mustard Compounds; D008466:Mechlorethamine
NITROGEN MUSTARDS; TUMORS/therapy